You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

pembrolizumab

Showing 26 - 50 of 1,067
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

PD-1 Refractory Advanced Melanoma Trial in Pittsburgh (Responder-Derived Fecal microbiota transplantation (R-FMT, Pembrolizumab,

Not yet recruiting
  • PD-1 Refractory Advanced Melanoma
  • Responder-Derived Fecal microbiota transplantation (R-FMT
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 1, 2023

Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer, Stage II Lung Cancer Trial in Nashville (drug, biological,

Not yet recruiting
  • Limited Stage Lung Small Cell Carcinoma
  • +3 more
  • Nashville, Tennessee
    Vanderbilt University/Ingram Cancer Center
Nov 10, 2023

NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +4 more
  • MK-2870
  • +2 more
  • (no location specified)
Sep 15, 2023

Head and Neck Squamous Cell Carcinoma Trial in Baltimore (Pembrolizumab, IO102-103)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Baltimore, Maryland
    Johns Hopkins University
Aug 2, 2023

Colorectal Cancer Trial (Pembrolizumab)

Recruiting
  • Colorectal Cancer
  • Pembrolizumab
  • Amsterdam, Netherlands
    Netherlands Cancer Institute
Jan 3, 2023

Head Neck, Squamous Cell Carcinoma of Head and Neck Trial in Houston (Pembrolizumab, Magrolimab, cetuximab)

Not yet recruiting
  • Head Neck
  • Squamous Cell Carcinoma of Head and Neck
  • Pembrolizumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 14, 2023

Triple Negative Breast Cancer Trial (Sacituzumab govitecan, Pembrolizumab)

Not yet recruiting
  • Triple Negative Breast Cancer
  • Sacituzumab govitecan
  • Pembrolizumab
  • (no location specified)
Oct 5, 2023

Oligometastatic Squamous Cell Carcinoma of the Head and Neck Trial (Pembrolizumab, stereotattic ablation radiotherapy (SABR))

Not yet recruiting
  • Oligometastatic Squamous Cell Carcinoma of the Head and Neck
  • Pembrolizumab
  • stereotattic ablation radiotherapy (SABR)
  • (no location specified)
Apr 14, 2023

Renal Cancer, Kidney Cancer, Renal Cell Carcinoma Trial in Aurora (Axitinib, Pembrolizumab)

Not yet recruiting
  • Renal Cancer
  • +3 more
  • Aurora, Colorado
    University of Colorado Cancer Center
Jul 24, 2023

Head and Neck Squamous Cell Carcinoma Trial in Saint Louis (Tazemetostat, Pembrolizumab)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Saint Louis, Missouri
    Washington University School of Medicine
Oct 26, 2022

Colorectal Cancer Trial in Koege (Influenza vaccine, Pembrolizumab)

Not yet recruiting
  • Colorectal Cancer
  • Influenza vaccine
  • Pembrolizumab
  • Koege, Zealand, Denmark
    Center for Surgical Science, Department of Surgery, Zealand Univ
Jun 9, 2023

Renal Pelvis and Ureter Urothelial Carcinoma Trial in Los Angeles (procedure, drug, biological)

Not yet recruiting
  • Renal Pelvis and Ureter Urothelial Carcinoma
  • Biopsy
  • +5 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Mar 15, 2023

Locally Advanced Esophageal and Gastric Cancers (EGC) Trial in Durham (Pembrolizumab)

Active, not recruiting
  • Locally Advanced Esophageal and Gastric Cancers (EGC)
  • Pembrolizumab
  • Durham, North Carolina
    Duke Cancer Center
Dec 7, 2022

Head and Neck Squamous Cell Carcinoma, Head Neck Cancer, Resectable Head and Neck Squamous Cell Carcinoma Trial in Boston

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +3 more
  • Pembrolizumab
  • +3 more
  • Boston, Massachusetts
  • +1 more
Feb 11, 2023

Recurrent Vulvar Cancer, Persistent Vulvar Cancer, Metastatic Vulva Cancer Trial (Pembrolizumab, Lenvatinib)

Not yet recruiting
  • Recurrent Vulvar Cancer
  • +3 more
  • (no location specified)
Jun 12, 2023

Advanced Solid Tumor, Metastatic Solid Tumor Trial in Nashville, Dallas, Fairfax (JZP898, Pembrolizumab)

Not yet recruiting
  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • Nashville, Tennessee
  • +2 more
Oct 26, 2023

Advanced Cancer, Non Small Cell Lung Cancer Trial (Tepotinib, Pembrolizumab)

Not yet recruiting
  • Advanced Cancer
  • Non Small Cell Lung Cancer
  • (no location specified)
Mar 28, 2023

Hodgkin Lymphoma Trial in Houston (Brentuximab vedotin, Doxorubicin Hydrochloride, Pembrolizumab)

Not yet recruiting
  • Hodgkin Lymphoma
  • Brentuximab vedotin
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 20, 2023

Non Hodgkin Lymphoma Trial in Philadelphia (Pembrolizumab)

Recruiting
  • Non Hodgkin Lymphoma
  • Pembrolizumab
  • Philadelphia, Pennsylvania
    Abamson Cancer Center of the University of Pennsylvania
Jan 9, 2023

Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome Trial in Ann Arbor (Pembrolizumab, Mogamulizumab)

Not yet recruiting
  • Cutaneous T Cell Lymphoma
  • Fungoides Mycosis Sezary Syndrome
  • Ann Arbor, Michigan
    University of Michigan Comprehensive Cancer Center
Jul 13, 2023

Mesotheliomas Pleural Trial in Amsterdam (Pembrolizumab, Lenvatinib)

Recruiting
  • Mesotheliomas Pleural
  • Amsterdam, Noord-Holland, Netherlands
    Antoni van Leeuwenhoekziekenhuis (NKI-AVL)
Jan 13, 2023

Metastatic Triple-Negative Breast Cancer Trial in Charlotte (Trilaciclib, Pembrolizumab, Gemcitabine)

Not yet recruiting
  • Metastatic Triple-Negative Breast Cancer
  • Charlotte, North Carolina
    Levine Cancer Institute
Aug 31, 2023

HPV-Related Squamous Cell Carcinoma, HNSCC Trial in London (VB10.16, Pembrolizumab)

Not yet recruiting
  • HPV-Related Squamous Cell Carcinoma
  • HNSCC
  • VB10.16
  • Pembrolizumab
  • London, United Kingdom
    East and North Hertfordshire NHS Trust Mount Vernon Hospital
Aug 24, 2023

Ovarian Carcinosarcoma, Uterine Carcinosarcoma Trial (Eribulin Mesylate, Pembrolizumab)

Not yet recruiting
  • Ovarian Carcinosarcoma
  • Uterine Carcinosarcoma
  • Eribulin Mesylate
  • Pembrolizumab
  • (no location specified)
Jan 31, 2023

Oropharyngeal Squamous Cell Carcinoma (SCC) Trial run by the National Cancer Institute (NCI) (PRGN-2009, Pembrolizumab)

Not yet recruiting
  • Oropharyngeal Squamous Cell Carcinoma (SCC)
  • PRGN-2009
  • Pembrolizumab
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 22, 2023